TapewireFind a company

person · Reporting owner

Anderson Kenneth Carl

Disclosed activity across 1 company

Tapewire entity
32615
SEC CIK
0001824862

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
C4 Therapeutics, Inc.CCCC · Entity 5503DirectorOctober 01, 2026October 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

C4 Therapeutics, Inc.

Report date October 01, 2026 · Filed October 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect75,612 Reported balance After 2026-10-01 transaction · row 1
1 source row

Row 1 · 2026-10-01 · Grant · Acquired 3,662 · Balance 75,612

F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.

Common StockSEC Table I · non-derivativeIndirectBy Kenneth C. Anderson 2021 Irrevocable Trust129,877 Reported balance Holding disclosure · report date 2026-10-01 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 129,877

F3: Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Kenneth C. Anderson 2015 Irrevocable Trust74,581 Reported balance Holding disclosure · report date 2026-10-01 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 74,581

F4: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Cynthia E. Anderson 2015 Irrevocable Trust74,581 Reported balance Holding disclosure · report date 2026-10-01 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 74,581

F5: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Kenneth C. Anderson Revocable Trust3,623 Reported balance Holding disclosure · report date 2026-10-01 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 3,623

F6: Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Cynthia E. Anderson Revocable Trust3,623 Reported balance Holding disclosure · report date 2026-10-01 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 3,623

F7: Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.

F3: Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F4: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F5: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F6: Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F7: Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 13, 2021 Filed Apr 14, 2021 20:39 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GiftCommon Stock 2,278 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-026665 · doc4.xml · nonDerivative · entry 2

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 47,316

F2 · shares: On April 13, 2021, Cynthia E. Anderson received a distribution of 2,278 shares of the Issuer's common stock from the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust.

Read SEC document
April 13, 2021 Filed Apr 14, 2021 20:39 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GiftCommon Stock 2,278 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-026665 · doc4.xml · nonDerivative · entry 1

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,435

F1 · shares: On April 13, 2021, Kenneth C. Anderson received a distribution of 2,278 shares of the Issuer's common stock from the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust.

Read SEC document
April 05, 2021 Filed Apr 6, 2021 20:31 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 233 $37.51 $8,739.83
Disclosure

SEC source: 0001209191-21-025665 · doc4.xml · nonDerivative · entry 1

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,157

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 5, 2021.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 21:34 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 Exercise / conversionStock Option (Right to Buy) · Derivative 889 $0.00 Strike: $4.98 $0.00
Disclosure

SEC source: 0001209191-21-005374 · doc4.xml · derivative · entry 11

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,446

Underlying: Common Stock · 889 shares

Expires 2030-07-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments, with the first installment vesting on October 1, 2020.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 21:34 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 Exercise / conversionStock Option (Right to Buy) · Derivative 121 $0.00 Strike: $2.11 $0.00
Disclosure

SEC source: 0001209191-21-005374 · doc4.xml · derivative · entry 10

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 121 shares

Expires 2026-07-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · shares: The Form 3 filed on October 1, 2020 included an incorrect number of underlying securities in Table II, Column 3 (118).

F7 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 20% of this option vested and became exercisable on January 1, 2017, with the remainder vesting in 16 equal quarterly installments thereafter.

F6 · derivative.underlying_shares: The Form 3 filed on October 1, 2020 included an incorrect number of underlying securities in Table II, Column 3 (118).

Read SEC document
January 22, 2021 Filed Jan 26, 2021 21:34 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 Exercise / conversionStock Option (Right to Buy) · Derivative 538 $0.00 Strike: $2.11 $0.00
Disclosure

SEC source: 0001209191-21-005374 · doc4.xml · derivative · entry 9

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,207

Underlying: Common Stock · 538 shares

Expires 2026-07-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 12.5% of this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 21:34 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 Exercise / conversionCommon Stock 889 $4.98 $4,427.22
Disclosure

SEC source: 0001209191-21-005374 · doc4.xml · nonDerivative · entry 3

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,924

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 21:34 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 Exercise / conversionCommon Stock 121 $2.11 $255.31
Disclosure

SEC source: 0001209191-21-005374 · doc4.xml · nonDerivative · entry 2

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 21:34 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 Exercise / conversionCommon Stock 538 $2.11 $1,135.18
Disclosure

SEC source: 0001209191-21-005374 · doc4.xml · nonDerivative · entry 1

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,914

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries B Preferred Stock · Derivative 142,857 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 12

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cynthia E. Anderson 2015 Irrevocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 16,939 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F5 · ownership.nature: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries B Preferred Stock · Derivative 142,857 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 11

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Kenneth C. Anderson 2015 Irrevocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 16,939 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F4 · ownership.nature: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries A Preferred Stock · Derivative 347,840 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 10

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cynthia E. Anderson 2016 Grantor Retained Annuity Trust

Disclosed balance after: 0

Underlying: Common Stock · 41,244 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F3 · ownership.nature: Shares held the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries A Preferred Stock · Derivative 347,840 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 9

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Kenneth C. Anderson 2016 Grantor Retained Annuity Trust

Disclosed balance after: 0

Underlying: Common Stock · 41,244 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries A Preferred Stock · Derivative 152,160 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 8

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Common Stock · 18,040 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries A Preferred Stock · Derivative 152,160 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 7

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,040 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 16,939 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 6

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cynthia E. Anderson 2015 Irrevocable Trust

Disclosed balance after: 16,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F5 · ownership.nature: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 16,939 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 5

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Kenneth C. Anderson 2015 Irrevocable Trust

Disclosed balance after: 16,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F4 · ownership.nature: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 41,244 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 4

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cynthia E. Anderson 2016 Grantor Retained Annuity Trust

Disclosed balance after: 63,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F3 · ownership.nature: Shares held the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 41,244 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 3

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Kenneth C. Anderson 2016 Grantor Retained Annuity Trust

Disclosed balance after: 63,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 18,040 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 2

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 45,038

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Read SEC document
October 06, 2020 Filed Oct 7, 2020 01:27 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 18,040 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 1

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,376

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

Read SEC document
October 01, 2020 Filed Oct 6, 2020 01:00 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 17,786 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-027443 · doc4.xml · derivative · entry 1

Anderson Kenneth Carl · CIK 0001824862 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,786

Underlying: Common Stock · 17,786 shares

Expires 2030-09-30

F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.